TBI remains one of the world's most under-diagnosed medical conditions, underscoring the need for rapid, objective diagnostic tools.
TBI affects over 69 million people globally each year. Yet it remains largely invisible — current diagnosis relies on subjective symptom checklists and bulky neuroimaging technology unavailable outside major hospitals.
Clinicians on sports sidelines, military medics in the field, and emergency physicians in regional hospitals are making life-altering decisions with inadequate tools. We're changing that.
How It Works
Collect
A simple fingerstick blood sample taken at the PoC — no specialised laboratory training required.
Analyse
GLIA's proprietary platform detects and quantifies miRNA biomarkers that signal brain injury.
Know
Receive an objective, biologically-grounded result within minutes — enabling confident clinical decisions.
Grounded in Rigorous Molecular Science
GLIA's platform combines deep molecular biology research with pragmatic engineering to produce a tool that works where and when it matters most — at the PoC.
Proprietary miRNA Biomarkers
Our platform detects up to 7 specific miRNA signatures validated across 5 clinical studies and 4 peer-reviewed publications. These signals go beyond traditional protein biomarkers, providing objective biological evidence of brain injury and recovery. Unlike subjective cognitive tests, our biological approach requires no baseline testing prior to injury.
PoC Platform
A compact, intuitive handheld device combining novel electrochemical sensing with single-use disposable cartridges. Portable, battery-powered, and built for real-world conditions — from locker rooms to field hospitals.
Regulatory Pathway
GLIA has completed an independent regulatory strategy review and is preparing for FDA Pre-Submission engagement to confirm intended use, predicate suitability, validation requirements and the appropriate 510(k) or De Novo pathway. Australian and European pathways will be progressed under the TGA framework and EU IVDR respectively.
Building a Body of Evidence
GLIA's platform is grounded in rigorous clinical research. An earlier electrochemical proof-of-concept demonstrated correlation with laboratory PCR measurements. GLIA is now translating that work into an integrated handheld MVP and a manufacturable disposable cartridge. Further validation is underway with leading US biobanks, military special operations, and professional sports organisations. We are assembling the data required to support regulatory submission and clinical adoption across the settings where TBI care matters most.
Clinical Studies
Biomarker evidence has been generated across five clinical studies, including acute TBI, mTBI and longitudinal recovery cohorts, with four peer-reviewed publications.
Peer-Reviewed Publications
Published and unpublished research supporting the biological rationale and diagnostic performance of our miRNA biomarker panel.
Proprietary Biomarkers
Specific miRNA signatures selected for sensitivity to brain injury and biological specificity.
Plasma micro-RNA biomarkers for diagnosis and prognosis after traumatic brain injury: A pilot study.
Micro-RNA levels and symptom profile after mild traumatic brain injury: A longitudinal cohort study.
MicroRNA biomarkers for diagnosis of mild traumatic brain injury and prediction of persistent symptoms: A prospective cohort study.
MicroRNA Biomarkers on Day of Injury Among Patients with Post Concussive Symptoms at 28-Days: A Prospective Cohort Study.
Partnering with healthcare, defence, sport and industry to bring objective TBI diagnostics to the point of care.
Momentum From Research to Market
A Defensible, Translation-Ready Position
A triple-layer IP strategy: an exclusive worldwide licence covering the foundational miRNA biomarker family, plus two GLIA-owned patent families covering the point-of-care platform and diagnostic/prognostic methods. Existing protein biomarker tests address an important acute CT-triage need. GLIA is being developed as a complementary miRNA platform with potential applications in diagnosis, prognosis and longitudinal recovery monitoring, subject to further validation and regulatory clearance.
TRL 7 Science
Biology largely answered — focus now on commercial translation.
Granted Patents
Granted across several territories/jurisdictions, protecting the biomarkers.
Proprietary PoC IP
GLIA-owned: electrochemical sensing + disposable cartridge. PCT successfully filed in several territories/jurisdictions.
MOU and Letters of Support
From multiple sporting codes spanning Australia and the US.
FDA Pathway
Precedent set by Abbott TBI clearance.
Three Patent Families — granted and filed
An exclusive worldwide licence over the foundational miRNA biomarker family, plus two GLIA-owned patent families covering the point-of-care platform and diagnostic/prognostic methods.
*Unitary Patent covering 17 EU states, plus validated in Czechia, Spain and the UK. In force through 2035.
Covers GLIA's point-of-care diagnostic platform. Filed 2024; expiry 2044.
Covers diagnostic and prognostic methods for TBI. Filed 2024; expiry 2044.
Comparing Today's Technologies
Existing approaches address fragments of the TBI challenge — from subjective bedside exams to hospital imaging and protein-based bleed triage. GLIA's miRNA PoC platform is designed to cover the full care pathway from injury through recovery, in settings where the standard of care cannot reach.
Standard Clinical Assessment
Symptom-based and subjective assessment of clinical signs and cognition.
- •Subjective and inconsistent; low–moderate sensitivity for mTBI/concussion.
- •High dependence on clinical expertise.
- •Limited for recovery monitoring and return-to-activity (RTA) support.
Imaging (CT / MRI)
Gold-standard structural imaging for intracranial bleeding and structural injury.
- •Often normal in mTBI/concussion; limited sensitivity for mild injury.
- •Hospital-based, low portability; time to result in hours.
- •High cost and resource intensity; limited for recovery monitoring and RTA support.
- •Generally only available in urban centres.
Protein biomarker tests and platforms — including Abbott i-STAT TBI
Protein biomarker test (e.g., Abbott i-STAT TBI), measuring GFAP and UCH-L1 blood proteins.
- •Variable sensitivity for mTBI/concussion; primarily focused on acute injury/bleeding risk.
- •Moderate portability and dependence on clinical expertise.
- •Moderate cost and resource intensity; limited for recovery monitoring and RTA support.
Oculogica
Eye-tracking (EyeBOX®) concussion diagnostic.
- •Reported use may be constrained by significant ocular conditions (strabismus, cataracts, poor acuity); performance may be affected by ADHD or intoxication.
- •Requires dedicated hardware (camera, screen, analysis unit) and clinician training.
- •Evidence for long-term outcome prediction or RTP was limited in the published literature reviewed.
BrainScope
Portable EEG-based brain injury assessment.
- •Requires specialised EEG headset, tablet and trained operator — limiting low-resource use.
- •Evidence for long-term outcome or cumulative / repeat-injury prediction was limited in the published literature reviewed.
- •Assesses functional impairment rather than the underlying biological injury mechanism.
Disclaimer
Competitor comparisons are based on publicly available information available as of July 2026. Product specifications, capabilities, indications for use, regulatory status, and commercial positioning may have changed since that date. Data has been compiled from publicly available manufacturer publications, regulatory databases, peer-reviewed literature, and company websites.
Company and product names are trademarks of their respective owners. This comparison is provided for general informational purposes only and is not intended to misrepresent, disparage, or imply superiority over any competing product. Readers should refer to the manufacturers' official documentation and applicable regulatory authorities for the most current information. Any comparison reflects GLIA's interpretation of publicly available information and should not be relied upon as a substitute for independent clinical, regulatory, or commercial evaluation.
Alfred Hospital
CSIRO
Genesys
Macquarie University
ADF and US DoD
NFL organisation
Four Critical Use Settings
Emergency Medicine
Rapid triage for patients presenting with head trauma. Enables early identification of significant brain injury, supporting faster and more confident referral and intervention decisions.
Sport & Athletics
Objective concussion testing at the point of injury (POI) — empowering team medics, physios, and sports doctors to make return-to-play (RTP) decisions backed by biological data.
Military & Defence
Blast-related TBI (B(TBI)) is a signature injury of modern conflict. GLIA's portable platform enables field medics to rapidly screen personnel in remote/austere environments, guiding duty-of-care decisions.
Regional & Remote/Austere Health
Where laboratory infrastructure is hours or days away, GLIA brings equitable, rapid brain-injury diagnostics to communities too often left behind — from outback Australia to remote/austere global settings.
Future expansion: aged care and community health settings.
Partner With Us
The conditions for adoption have never been stronger.
- →FDA precedent demonstrated for TBI clearance.
- →Growing awareness of mTBI and brain health across sport and society.
- →Increased defence focus on blast exposure and Veteran welfare.
- →Expansion of women's sport — and women's mTBI research.
- →Rising demand for rapid diagnostics in regional and remote/austere settings.
Better access for the communities left behind.
Explore the technology.
Or partner with GLIA.
Learn how our miRNA biomarker platform delivers objective TBI results in under 20 minutes — or start a conversation about piloting, partnering, or investing.
Let's Start a Conversation
Whether you're a clinician, researcher, investor, or industry partner — we'd love to hear from you.
